Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/pfizer-inc-be3cd920-aa3d-4c60-8a77-2cf2cec77e91">Pfizer </a>is navigating a significant post-pandemic transition, marked by a sharp decline in COVID-19 product revenues (Comirnaty vaccine and Paxlovid antiviral). The company's financial performance reflects this shift, with a strategic pivot towards its non-COVID product portfolio.</li>
 <li>A key pillar of future growth is the significant investment in oncology, highlighted by the $43 billion acquisition of Seagen. This move doubles Pfizer's early-stage oncology pipeline and establishes a strong presence in the innovative antibody-drug conjugate (ADC) space, which is expected to be a major revenue contributor by 2030.</li>
 <li>The company faces a considerable patent cliff, with key blockbusters like Eliquis, Ibrance, and Xeljanz facing loss of exclusivity between 2026 and 2028, potentially eroding $17-$18 billion in annual revenue. Management's strategy to counteract this involves aggressive cost-cutting programs, advancing its R&amp;D pipeline, and leveraging new acquisitions to bridge the impending revenue gap.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Pfizer is navigating a significant post-pandemic transition, marked by a sharp decline in COVID-19 product revenues (Comirnaty vaccine and Paxlovid antiviral). The company's financial performance reflects this shift, with a strategic pivot towards its non-COVID product portfolio.
  A key pillar of future growth is the significant investment in oncology, highlighted by the $43 billion acquisition of Seagen. This move doubles Pfizer's early-stage oncology pipeline and establishes a strong presence in the innovative antibody-drug conjugate (ADC) space, which is expected to be a major revenue contributor by 2030.
  The company faces a considerable patent cliff, with key blockbusters like Eliquis, Ibrance, and Xeljanz facing loss of exclusivity between 2026 and 2028, potentially eroding $17-$18 billion in annual revenue. Management's strategy to counteract this involves aggressive cost-cutting programs, advancing its R&amp;D pipeline, and leveraging new acquisitions to bridge the impending revenue gap.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul>
 <li>Pfizer is navigating a significant post-pandemic transition, with declining revenues from its COVID-19 products (Comirnaty and Paxlovid) pressuring overall growth. The company's strategic focus has pivoted to its non-COVID portfolio and advancing its pipeline, particularly in high-growth areas like oncology and obesity.</li>
 <li>The acquisition of Seagen has substantially bolstered Pfizer's oncology pipeline, adding a portfolio of antibody-drug conjugates (ADCs) and positioning the company as a leader in cancer treatment. This is a critical component of its strategy to offset revenue losses from upcoming patent expirations.</li>
 <li>While facing near-term headwinds from patent cliffs on key drugs like Eliquis and Ibrance, Pfizer is making substantial R&amp;D investments and pursuing strategic licensing deals to build its next generation of blockbusters. The company's valuation appears discounted relative to peers, reflecting the market's uncertainty regarding its long-term growth trajectory.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Pfizer is navigating a significant post-pandemic transition, with declining revenues from its COVID-19 products (Comirnaty and Paxlovid) pressuring overall growth. The company's strategic focus has pivoted to its non-COVID portfolio and advancing its pipeline, particularly in high-growth areas like oncology and obesity.
  The acquisition of Seagen has substantially bolstered Pfizer's oncology pipeline, adding a portfolio of antibody-drug conjugates (ADCs) and positioning the company as a leader in cancer treatment. This is a critical component of its strategy to offset revenue losses from upcoming patent expirations.
  While facing near-term headwinds from patent cliffs on key drugs like Eliquis and Ibrance, Pfizer is making substantial R&amp;D investments and pursuing strategic licensing deals to build its next generation of blockbusters. The company's valuation appears discounted relative to peers, reflecting the market's uncertainty regarding its long-term growth trajectory.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.</li>
<li>In terms of quantity and quality of innovations <a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>  and <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna (MRNA US)</a>  are best positioned. Among private companies Senda Biosciences screened well. </li>
<li>Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.</li>
</ul>


In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US)  and Moderna (MRNA US)  are best positioned. Among private companies Senda Biosciences screened well. 
Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.


Who Are Leading the Charge in the RNAissance of Medicine

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/3sbio-inc" target="_blank" data-smartkarma-citation="entities:459:1" rel="noopener">3SBio Inc (1530 HK)</a> signed an outlicensing deal worth more than $6B with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707. Since signing the deal, 3SBio shares rallied more than 55%.</li>
<li>Considering deals signed with Chinese companies for bispecific antibody drug candidates in recent times, 3SBio seems to have secured best valuation for its asset.</li>
<li>Initiation of global trial of SSGJ-707 and data readout from its ongoing China trials for additional indications, continued strong financial performance, and new approvals are upcoming catalysts.</li>
</ul>



3SBio Inc (1530 HK) signed an outlicensing deal worth more than $6B with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707. Since signing the deal, 3SBio shares rallied more than 55%.
Considering deals signed with Chinese companies for bispecific antibody drug candidates in recent times, 3SBio seems to have secured best valuation for its asset.
Initiation of global trial of SSGJ-707 and data readout from its ongoing China trials for additional indications, continued strong financial performance, and new approvals are upcoming catalysts.


3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?

United States

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pfizer (PFE UN)

Primer: Pfizer (PFE UN) - Aug 2026

Pfizer is navigating a significant post-pandemic transition, marked by a sharp decline in COVID-19 product revenues (Comirnaty vaccine and...

αSK Primers

Primer: Pfizer Inc (PFE US) - Aug 2026

Pfizer is navigating a significant post-pandemic transition, with declining revenues from its COVID-19 products (Comirnaty and Paxlovid)...

αSK Primers

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?

3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Pfizer (PFE UN) - Aug 2026

Pfizer is navigating a significant post-pandemic transition, marked by a sharp decline in COVID-19 product revenues (Comirnaty vaccine and...

αSK Primers

Primer: Pfizer Inc (PFE US) - Aug 2026

Pfizer is navigating a significant post-pandemic transition, with declining revenues from its COVID-19 products (Comirnaty and Paxlovid)...

αSK Primers

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?

​3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...

Tina Banerjee

3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...